JP2005514330A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005514330A5 JP2005514330A5 JP2003530659A JP2003530659A JP2005514330A5 JP 2005514330 A5 JP2005514330 A5 JP 2005514330A5 JP 2003530659 A JP2003530659 A JP 2003530659A JP 2003530659 A JP2003530659 A JP 2003530659A JP 2005514330 A5 JP2005514330 A5 JP 2005514330A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- butyl
- difluorobenzyl
- optionally substituted
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052736 halogen Inorganic materials 0.000 claims 62
- 150000002367 halogens Chemical class 0.000 claims 62
- 125000000217 alkyl group Chemical group 0.000 claims 59
- 125000004663 dialkyl amino group Chemical group 0.000 claims 36
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 36
- 125000000623 heterocyclic group Chemical group 0.000 claims 30
- 125000001072 heteroaryl group Chemical group 0.000 claims 25
- 206010012289 Dementia Diseases 0.000 claims 22
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 16
- -1 substituted Chemical class 0.000 claims 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 10
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 claims 10
- 208000024827 Alzheimer disease Diseases 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 230000003412 degenerative effect Effects 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 6
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 6
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 6
- BHACQVFKSPPDLM-UHFFFAOYSA-N 3-n,3-n-dipropylbenzene-1,3,5-tricarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C(N)=O)=CC(C(N)=O)=C1 BHACQVFKSPPDLM-UHFFFAOYSA-N 0.000 claims 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims 5
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 4
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 4
- 201000010374 Down Syndrome Diseases 0.000 claims 4
- 241000257303 Hymenoptera Species 0.000 claims 4
- 206010044688 Trisomy 21 Diseases 0.000 claims 4
- 210000004227 basal ganglia Anatomy 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 230000001054 cortical effect Effects 0.000 claims 4
- 230000007850 degeneration Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 210000004558 lewy body Anatomy 0.000 claims 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims 4
- 230000002792 vascular Effects 0.000 claims 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 3
- 125000001414 1,2,4-triazol-5-yl group Chemical group [H]N1N=C([H])N=C1[*] 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 150000003857 carboxamides Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 2
- 208000036536 dutch type ABeta amyloidosis Diseases 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims 2
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 125000001506 1,2,3-triazol-5-yl group Chemical group [H]N1N=NC([H])=C1[*] 0.000 claims 1
- IHDYGLQPUPOOQF-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-1,2,4-triazol-5-yl)pentan-2-yl]indole-6-carboxamide Chemical compound C1=C2N(CCCC)C=CC2=CC=C1C(=O)NC(C(O)CCC=1NN=CN=1)CC1=CC(F)=CC(F)=C1 IHDYGLQPUPOOQF-UHFFFAOYSA-N 0.000 claims 1
- SFXJLXCQVDVPMQ-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-indol-2-yl)pentan-2-yl]-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC3=CC=CC=C3C=1)C=C2C1=NC=CO1 SFXJLXCQVDVPMQ-UHFFFAOYSA-N 0.000 claims 1
- DCCIFJLXPUVSTK-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrazol-5-yl)pentan-2-yl]-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=CC=1)C=C2C1=NC=CO1 DCCIFJLXPUVSTK-UHFFFAOYSA-N 0.000 claims 1
- WUSLPRMRFGUDMP-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrazol-5-yl)pentan-2-yl]indole-6-carboxamide Chemical compound C1=C2N(CCCC)C=CC2=CC=C1C(=O)NC(C(O)CCC=1NN=CC=1)CC1=CC(F)=CC(F)=C1 WUSLPRMRFGUDMP-UHFFFAOYSA-N 0.000 claims 1
- CBZUAAHUVIPSKY-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrrol-2-yl)pentan-2-yl]-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC=CC=1)C=C2C1=NC=CO1 CBZUAAHUVIPSKY-UHFFFAOYSA-N 0.000 claims 1
- PJEOKKZDRSEKFU-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrrol-2-yl)pentan-2-yl]indole-6-carboxamide Chemical compound C1=C2N(CCCC)C=CC2=CC=C1C(=O)NC(C(O)CCC=1NC=CC=1)CC1=CC(F)=CC(F)=C1 PJEOKKZDRSEKFU-UHFFFAOYSA-N 0.000 claims 1
- WUOSNJNGPXVMCH-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(2h-triazol-4-yl)pentan-2-yl]-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=NC=1)C=C2C1=NC=CO1 WUOSNJNGPXVMCH-UHFFFAOYSA-N 0.000 claims 1
- XQZDLOHEQKVFDU-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(2h-triazol-4-yl)pentan-2-yl]indole-6-carboxamide Chemical compound C1=C2N(CCCC)C=CC2=CC=C1C(=O)NC(C(O)CCC=1NN=NC=1)CC1=CC(F)=CC(F)=C1 XQZDLOHEQKVFDU-UHFFFAOYSA-N 0.000 claims 1
- RPKPQXPESCGNCV-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(5-oxopyrrolidin-2-yl)pentan-2-yl]-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC1NC(=O)CC1)C=C2C1=NC=CO1 RPKPQXPESCGNCV-UHFFFAOYSA-N 0.000 claims 1
- WDHCPNAREXWPPA-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(5-oxopyrrolidin-2-yl)pentan-2-yl]indole-6-carboxamide Chemical compound C1=C2N(CCCC)C=CC2=CC=C1C(=O)NC(C(O)CCC1NC(=O)CC1)CC1=CC(F)=CC(F)=C1 WDHCPNAREXWPPA-UHFFFAOYSA-N 0.000 claims 1
- HZQGLTSJPSXKIC-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(6-oxopiperidin-2-yl)pentan-2-yl]-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC1NC(=O)CCC1)C=C2C1=NC=CO1 HZQGLTSJPSXKIC-UHFFFAOYSA-N 0.000 claims 1
- BRBMTIKZRMBHLS-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(6-oxopiperidin-2-yl)pentan-2-yl]indole-6-carboxamide Chemical compound C1=C2N(CCCC)C=CC2=CC=C1C(=O)NC(C(O)CCC1NC(=O)CCC1)CC1=CC(F)=CC(F)=C1 BRBMTIKZRMBHLS-UHFFFAOYSA-N 0.000 claims 1
- KIKGANUEXHTONT-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxypropan-2-yl]-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NC(CO)CC=1C=C(F)C=C(F)C=1)C=C2C1=NC=CO1 KIKGANUEXHTONT-UHFFFAOYSA-N 0.000 claims 1
- PCMLQPLBUSSQCO-UHFFFAOYSA-N 1-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxypropan-2-yl]indole-6-carboxamide Chemical compound C1=C2N(CCCC)C=CC2=CC=C1C(=O)NC(CO)CC1=CC(F)=CC(F)=C1 PCMLQPLBUSSQCO-UHFFFAOYSA-N 0.000 claims 1
- UKFITBRXJWZDIF-UHFFFAOYSA-N 1-butyl-n-[2-(3,5-difluorophenyl)ethyl]-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NCCC=1C=C(F)C=C(F)C=1)C=C2C1=NC=CO1 UKFITBRXJWZDIF-UHFFFAOYSA-N 0.000 claims 1
- IHXWKLHECBKJEV-UHFFFAOYSA-N 1-butyl-n-[2-(3,5-difluorophenyl)ethyl]indole-6-carboxamide Chemical compound C1=C2N(CCCC)C=CC2=CC=C1C(=O)NCCC1=CC(F)=CC(F)=C1 IHXWKLHECBKJEV-UHFFFAOYSA-N 0.000 claims 1
- JISSPBPUVKICME-QFIPXVFZSA-N 1-n-[(2s)-1-(3,5-difluorophenyl)-3-hydroxypropan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)N[C@H](CO)CC=2C=C(F)C=C(F)C=2)=C1 JISSPBPUVKICME-QFIPXVFZSA-N 0.000 claims 1
- IRHDCWYPZODAGK-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-1,2,4-triazol-5-yl)pentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)CCC=2NN=CN=2)=C1 IRHDCWYPZODAGK-UHFFFAOYSA-N 0.000 claims 1
- XUXAJQGPGCMOEK-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-indol-2-yl)pentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)CCC=2NC3=CC=CC=C3C=2)=C1 XUXAJQGPGCMOEK-UHFFFAOYSA-N 0.000 claims 1
- BZKLEGILCVCVRW-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrazol-5-yl)pentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)CCC=2NN=CC=2)=C1 BZKLEGILCVCVRW-UHFFFAOYSA-N 0.000 claims 1
- PXVDKHFQHQUBCI-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrrol-2-yl)pentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)CCC=2NC=CC=2)=C1 PXVDKHFQHQUBCI-UHFFFAOYSA-N 0.000 claims 1
- QJWFUZFAVOWDGV-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(2h-triazol-4-yl)pentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)CCC=2NN=NC=2)=C1 QJWFUZFAVOWDGV-UHFFFAOYSA-N 0.000 claims 1
- CZAIKKJMEMJBHM-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(5-oxopyrrolidin-2-yl)pentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)CCC2NC(=O)CC2)=C1 CZAIKKJMEMJBHM-UHFFFAOYSA-N 0.000 claims 1
- FGCRREWITXOSDP-UHFFFAOYSA-N 1-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(6-oxopiperidin-2-yl)pentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)CCC2NC(=O)CCC2)=C1 FGCRREWITXOSDP-UHFFFAOYSA-N 0.000 claims 1
- YCMYEVYIGMWBBM-UHFFFAOYSA-N 1-n-[5-(1h-benzimidazol-2-yl)-1-(3,5-difluorophenyl)-3-hydroxypentan-2-yl]-5-methyl-3-n,3-n-dipropylbenzene-1,3-dicarboxamide Chemical compound CCCN(CCC)C(=O)C1=CC(C)=CC(C(=O)NC(CC=2C=C(F)C=C(F)C=2)C(O)CCC=2NC3=CC=CC=C3N=2)=C1 YCMYEVYIGMWBBM-UHFFFAOYSA-N 0.000 claims 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- NUQGGGIDFQWIFU-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-1,2,4-triazol-5-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=CN=1)C=C2C1=NC=CO1 NUQGGGIDFQWIFU-UHFFFAOYSA-N 0.000 claims 1
- OVJPUYVERNVDBJ-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-1,2,4-triazol-5-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=CN=1)C=C2C1=NC=CO1 OVJPUYVERNVDBJ-UHFFFAOYSA-N 0.000 claims 1
- NKYZEWBVEFZKMR-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-indol-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC3=CC=CC=C3C=1)C=C2C1=NC=CO1 NKYZEWBVEFZKMR-UHFFFAOYSA-N 0.000 claims 1
- YMWSLHJVFVZFLE-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-indol-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC3=CC=CC=C3C=1)C=C2C1=NC=CO1 YMWSLHJVFVZFLE-UHFFFAOYSA-N 0.000 claims 1
- NNDNYXNFAVYVMX-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-indol-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC3=CC=CC=C3C=1)C=C2C1=NC=CO1 NNDNYXNFAVYVMX-UHFFFAOYSA-N 0.000 claims 1
- IUKWKSGABPZERY-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrazol-5-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=CC=1)C=C2C1=NC=CO1 IUKWKSGABPZERY-UHFFFAOYSA-N 0.000 claims 1
- YNHWVRIOWYBQBZ-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrazol-5-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=CC=1)C=C2C1=NC=CO1 YNHWVRIOWYBQBZ-UHFFFAOYSA-N 0.000 claims 1
- HFXYFEKNOJYCRC-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrazol-5-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=CC=1)C=C2C1=NC=CO1 HFXYFEKNOJYCRC-UHFFFAOYSA-N 0.000 claims 1
- QKHGYICHUUVYGS-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrrol-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC=CC=1)C=C2C1=NC=CO1 QKHGYICHUUVYGS-UHFFFAOYSA-N 0.000 claims 1
- YSCCZYIQLYWITG-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrrol-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC=CC=1)C=C2C1=NC=CO1 YSCCZYIQLYWITG-UHFFFAOYSA-N 0.000 claims 1
- BNQYKUYVKHNHEH-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(1h-pyrrol-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC=CC=1)C=C2C1=NC=CO1 BNQYKUYVKHNHEH-UHFFFAOYSA-N 0.000 claims 1
- XRUXVYZGNDCMKV-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(2h-triazol-4-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=NC=1)C=C2C1=NC=CO1 XRUXVYZGNDCMKV-UHFFFAOYSA-N 0.000 claims 1
- LSRXGNNAUBZPAE-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(2h-triazol-4-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=NC=1)C=C2C1=NC=CO1 LSRXGNNAUBZPAE-UHFFFAOYSA-N 0.000 claims 1
- VTDUFWWEUCKCBF-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(2h-triazol-4-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NN=NC=1)C=C2C1=NC=CO1 VTDUFWWEUCKCBF-UHFFFAOYSA-N 0.000 claims 1
- GTMKLWQBKOTLHV-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(5-oxopyrrolidin-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC1NC(=O)CC1)C=C2C1=NC=CO1 GTMKLWQBKOTLHV-UHFFFAOYSA-N 0.000 claims 1
- GNJWTCDBLPZBSM-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(5-oxopyrrolidin-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC1NC(=O)CC1)C=C2C1=NC=CO1 GNJWTCDBLPZBSM-UHFFFAOYSA-N 0.000 claims 1
- QPEVICIBZKGDFL-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(5-oxopyrrolidin-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC1NC(=O)CC1)C=C2C1=NC=CO1 QPEVICIBZKGDFL-UHFFFAOYSA-N 0.000 claims 1
- VGCSKCKTGUNVKO-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(6-oxopiperidin-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC1NC(=O)CCC1)C=C2C1=NC=CO1 VGCSKCKTGUNVKO-UHFFFAOYSA-N 0.000 claims 1
- JSNGFLHVODTXRS-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(6-oxopiperidin-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC1NC(=O)CCC1)C=C2C1=NC=CO1 JSNGFLHVODTXRS-UHFFFAOYSA-N 0.000 claims 1
- PRCFBPVZVDCOHK-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxy-5-(6-oxopiperidin-2-yl)pentan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC1NC(=O)CCC1)C=C2C1=NC=CO1 PRCFBPVZVDCOHK-UHFFFAOYSA-N 0.000 claims 1
- WJRBJNQQTFGYSW-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxypropan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CO)CC=1C=C(F)C=C(F)C=1)C=C2C1=NC=CO1 WJRBJNQQTFGYSW-UHFFFAOYSA-N 0.000 claims 1
- AWKYLEDPGJKVBZ-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxypropan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CO)CC=1C=C(F)C=C(F)C=1)C=C2C1=NC=CO1 AWKYLEDPGJKVBZ-UHFFFAOYSA-N 0.000 claims 1
- MAFSYLQABRNGGZ-UHFFFAOYSA-N 4-butyl-n-[1-(3,5-difluorophenyl)-3-hydroxypropan-2-yl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NC(CO)CC=1C=C(F)C=C(F)C=1)C=C2C1=NC=CO1 MAFSYLQABRNGGZ-UHFFFAOYSA-N 0.000 claims 1
- IRJCDTSTOAETIP-UHFFFAOYSA-N 4-butyl-n-[2-(3,5-difluorophenyl)ethyl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NCCC=1C=C(F)C=C(F)C=1)C=C2C1=NC=CO1 IRJCDTSTOAETIP-UHFFFAOYSA-N 0.000 claims 1
- IDZQSGYIZVYJHD-UHFFFAOYSA-N 4-butyl-n-[2-(3,5-difluorophenyl)ethyl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NCCC=1C=C(F)C=C(F)C=1)C=C2C1=NC=CO1 IDZQSGYIZVYJHD-UHFFFAOYSA-N 0.000 claims 1
- FGVMSEHSENMHHK-UHFFFAOYSA-N 4-butyl-n-[2-(3,5-difluorophenyl)ethyl]-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NCCC=1C=C(F)C=C(F)C=1)C=C2C1=NC=CO1 FGVMSEHSENMHHK-UHFFFAOYSA-N 0.000 claims 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- JEMNNNQAPVQJSZ-UHFFFAOYSA-N n-[5-(1h-benzimidazol-2-yl)-1-(3,5-difluorophenyl)-3-hydroxypentan-2-yl]-1-butyl-5-(1,3-oxazol-2-yl)-3,4-dihydro-2h-quinoline-7-carboxamide Chemical compound CCCCN1CCCC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC3=CC=CC=C3N=1)C=C2C1=NC=CO1 JEMNNNQAPVQJSZ-UHFFFAOYSA-N 0.000 claims 1
- XDMZDMWZYKEEIR-UHFFFAOYSA-N n-[5-(1h-benzimidazol-2-yl)-1-(3,5-difluorophenyl)-3-hydroxypentan-2-yl]-4-butyl-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzothiazine-6-carboxamide Chemical compound CCCCN1CCSC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC3=CC=CC=C3N=1)C=C2C1=NC=CO1 XDMZDMWZYKEEIR-UHFFFAOYSA-N 0.000 claims 1
- UZAOATGNJCHHEW-UHFFFAOYSA-N n-[5-(1h-benzimidazol-2-yl)-1-(3,5-difluorophenyl)-3-hydroxypentan-2-yl]-4-butyl-8-(1,3-oxazol-2-yl)-2,3-dihydro-1,4-benzoxazine-6-carboxamide Chemical compound CCCCN1CCOC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC3=CC=CC=C3N=1)C=C2C1=NC=CO1 UZAOATGNJCHHEW-UHFFFAOYSA-N 0.000 claims 1
- AQCYABAJBRLJTA-UHFFFAOYSA-N n-[5-(1h-benzimidazol-2-yl)-1-(3,5-difluorophenyl)-3-hydroxypentan-2-yl]-4-butyl-8-(1,3-oxazol-2-yl)-2,3-dihydro-1h-quinoxaline-6-carboxamide Chemical compound CCCCN1CCNC2=C1C=C(C(=O)NC(CC=1C=C(F)C=C(F)C=1)C(O)CCC=1NC3=CC=CC=C3N=1)C=C2C1=NC=CO1 AQCYABAJBRLJTA-UHFFFAOYSA-N 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 0 C*(C)c1cnn[n]1 Chemical compound C*(C)c1cnn[n]1 0.000 description 2
- YIDCITOHTLPMMZ-UHFFFAOYSA-N CC(C)(C)c1ccn[nH]1 Chemical compound CC(C)(C)c1ccn[nH]1 YIDCITOHTLPMMZ-UHFFFAOYSA-N 0.000 description 1
- XPMMAKUHNMSONL-YFKPBYRVSA-N C[C@@H](CCC1)NC1=O Chemical compound C[C@@H](CCC1)NC1=O XPMMAKUHNMSONL-YFKPBYRVSA-N 0.000 description 1
- PZKFSRWSQOQYNR-UHFFFAOYSA-N Cc1ncn[nH]1 Chemical compound Cc1ncn[nH]1 PZKFSRWSQOQYNR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32440701P | 2001-09-24 | 2001-09-24 | |
| PCT/US2002/030231 WO2003027068A2 (en) | 2001-09-24 | 2002-09-24 | Substituted amines for the treatment of neurological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005514330A JP2005514330A (ja) | 2005-05-19 |
| JP2005514330A5 true JP2005514330A5 (https=) | 2006-01-05 |
Family
ID=23263441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003530659A Pending JP2005514330A (ja) | 2001-09-24 | 2002-09-24 | アルツハイマー病治療のための置換アミン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060100196A1 (https=) |
| EP (1) | EP1430032A2 (https=) |
| JP (1) | JP2005514330A (https=) |
| AU (1) | AU2002356525A1 (https=) |
| BR (1) | BR0212787A (https=) |
| CA (1) | CA2461603A1 (https=) |
| MX (1) | MXPA04002785A (https=) |
| WO (1) | WO2003027068A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ534757A (en) | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| CN1805938B (zh) | 2003-06-17 | 2010-06-16 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 |
| HUE028976T2 (en) | 2003-06-17 | 2017-02-28 | Arena Pharm Inc | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
| MXPA06001558A (es) * | 2003-08-08 | 2006-05-15 | Schering Corp | Inhibidores de amina ciclica bace-1 que poseen un sustituyente heterociclico. |
| CA2548849A1 (en) | 2003-12-19 | 2005-07-21 | Merck & Co., Inc. | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease |
| WO2005103020A1 (en) * | 2004-04-20 | 2005-11-03 | Merck & Co., Inc. | 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| CA2570995A1 (en) * | 2004-06-15 | 2006-01-05 | Merck & Co., Inc. | Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease |
| SI1838677T1 (sl) | 2004-12-21 | 2010-01-29 | Arena Pharm Inc | Kristalne oblike (R)-8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin hidroklorida |
| KR20080015079A (ko) | 2005-04-08 | 2008-02-18 | 코멘티스, 인코포레이티드 | 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법 |
| JP5426878B2 (ja) * | 2005-05-24 | 2014-02-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｐ−結合カセットトランスポーターのモジュレーター |
| EP2471779A1 (en) | 2006-04-03 | 2012-07-04 | Arena Pharmaceuticals, Inc. | Process for the resolution of a mixture of (R)- and (S)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| US8299241B2 (en) | 2006-12-05 | 2012-10-30 | Arena Pharmaceuticals, Inc. | Processes for preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates thereof |
| CN102015591B (zh) | 2008-03-04 | 2014-01-29 | 艾尼纳制药公司 | 制备与5-ht2c激动剂(r)-8-氯-1-甲基-2，3，4，5-四氢-1h-3-苯并氮杂卓相关的中间体的方法 |
| US8952197B2 (en) | 2009-06-18 | 2015-02-10 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
| KR20130112848A (ko) | 2010-06-02 | 2013-10-14 | 아레나 파마슈티칼스, 인크. | 5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법 |
| EP3485878A1 (en) | 2010-09-01 | 2019-05-22 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
| KR20130138770A (ko) | 2010-09-01 | 2013-12-19 | 아레나 파마슈티칼스, 인크. | 광학적으로 활성 산을 갖는 로르카세린의 염 |
| KR20140091458A (ko) | 2010-09-01 | 2014-07-21 | 아레나 파마슈티칼스, 인크. | 신장 손상을 갖는 개체에 대한 로카세린의 투여 |
| JP2013536859A (ja) | 2010-09-01 | 2013-09-26 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ｈｔ２ｃアゴニストの非吸湿性塩 |
| WO2014058441A1 (en) | 2012-10-09 | 2014-04-17 | Arena Pharmaceuticals, Inc. | Method of weight management |
| EP2982670B1 (en) * | 2013-04-04 | 2018-11-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2016010092A1 (ja) * | 2014-07-16 | 2016-01-21 | 国立研究開発法人科学技術振興機構 | ベンゾチアゾール化合物及びこれを含有する医薬 |
| CA3002416C (en) | 2015-10-23 | 2023-10-24 | Vifor (International) Ag | Benzimidazolyl derivatives for use as ferroportin inhibitors |
| JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| EP4392406A4 (en) * | 2021-09-30 | 2025-07-30 | TroBio Therapeutics Pty Ltd | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE |
| CN117229257B (zh) * | 2022-06-06 | 2026-01-30 | 中国药科大学 | 间氨磺酰苯甲酰胺类化合物及制法、药物组合物和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2057145A (en) * | 1934-02-09 | 1936-10-13 | Firm Chem Fab Grunau Landshoff | Pharmaceutical preparation for stimulating the respiratory centre and increasing the circulation |
| US2971027A (en) * | 1956-08-30 | 1961-02-07 | California Research Corp | Diamides of terephthalic acid |
| US4562201A (en) * | 1982-07-26 | 1985-12-31 | American Hospital Supply Corporation | Aminomethyl benzanilides |
| CA1338012C (en) * | 1987-04-27 | 1996-01-30 | John Michael Mccall | Pharmaceutically active amines |
| US5399565A (en) * | 1990-07-17 | 1995-03-21 | Eli Lilly And Company | Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof |
| US5885985A (en) * | 1993-03-23 | 1999-03-23 | Astra Aktiebolag | Guanidine derivatives useful in therapy |
| US5750702A (en) * | 1993-10-27 | 1998-05-12 | Neurogen Corporation | Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands |
| CA2193388C (en) * | 1994-06-29 | 2005-07-26 | Bertrand L. Chenard | Aryl and heteroaryl alkoxynaphthalene derivatives |
| US5741819A (en) * | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
| PL335235A1 (en) * | 1997-02-19 | 2000-04-10 | Berlex Lab | N-heterocyclic derivatives as nos inhibitors |
| JP2001524468A (ja) * | 1997-11-21 | 2001-12-04 | エヌピーエス ファーマシューティカルズ インコーポレーテッド | 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト |
| GB9800750D0 (en) * | 1998-01-14 | 1998-03-11 | Lilly Co Eli | Pharmaceutical compound |
| JP2002540206A (ja) * | 1999-03-11 | 2002-11-26 | ニューロゲン コーポレイション | アリールの縮合した２，４−二置換ピリジン：ｎｋ３受容体リガンド |
| CN1361768A (zh) * | 1999-06-02 | 2002-07-31 | Nps药物有限公司 | 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途 |
| WO2000078730A1 (en) * | 1999-06-23 | 2000-12-28 | Ajinomoto Co., Inc. | Novel dihydropyrimidine derivatives |
| EP1218358B1 (en) * | 1999-09-23 | 2006-09-13 | AstraZeneca AB | Therapeutic quinazoline compounds |
| EP1268484A1 (en) * | 2000-03-17 | 2003-01-02 | Novo Nordisk A/S | Condensed imidazoles as histamine h3 receptor ligands |
| AUPQ969800A0 (en) * | 2000-08-28 | 2000-09-21 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| WO2002032896A1 (en) * | 2000-10-16 | 2002-04-25 | Novo Nordisk A/S | Furazanyl-triazole derivates for the treatment of diseases |
| HU227197B1 (en) * | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| JP2004532187A (ja) * | 2001-01-25 | 2004-10-21 | ギルフォード ファーマシュウティカルズ インコーポレイテッド | 三置換カルボサイクリックサイクロフィリン結合化合物とその用途 |
| EP1435948A1 (en) * | 2001-08-06 | 2004-07-14 | Pharmacia Italia S.p.A. | Aminoisoxazole derivatives active as kinase inhibitors |
| TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| WO2003037900A2 (en) * | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazolopyrimidines |
| AU2002352868A1 (en) * | 2001-11-27 | 2003-06-10 | Merck & Co., Inc. | 4-aminoquinoline compounds |
| HUP0105406A3 (en) * | 2001-12-21 | 2003-12-29 | Sanofi Aventis | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
-
2002
- 2002-09-24 EP EP02799615A patent/EP1430032A2/en not_active Withdrawn
- 2002-09-24 AU AU2002356525A patent/AU2002356525A1/en not_active Abandoned
- 2002-09-24 MX MXPA04002785A patent/MXPA04002785A/es not_active Application Discontinuation
- 2002-09-24 WO PCT/US2002/030231 patent/WO2003027068A2/en not_active Ceased
- 2002-09-24 BR BR0212787-3A patent/BR0212787A/pt not_active IP Right Cessation
- 2002-09-24 US US10/490,682 patent/US20060100196A1/en not_active Abandoned
- 2002-09-24 JP JP2003530659A patent/JP2005514330A/ja active Pending
- 2002-09-24 CA CA002461603A patent/CA2461603A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005514330A5 (https=) | ||
| US9096565B2 (en) | Inhibitors of histone deacetylase | |
| ES2977656T3 (es) | Inhibidores de KDM1A para el tratamiento de enfermedades | |
| KR20220085798A (ko) | Trmp8 조절제로서의 치환된 아자사이클 | |
| TWI309165B (en) | Novel morpholine compounds | |
| JO2371B1 (en) | 4-phenyl-pyridine derivatives | |
| NO20064151L (no) | Nye forbindelser | |
| TWI648272B (zh) | 經取代之四氫咔唑及咔唑甲醯胺化合物 | |
| SE0104332D0 (sv) | Therapeutic agents | |
| IL107946A (en) | Pyrazoles and pyrazolepyrimidines and pharmaceutical compositions containing them | |
| ATE361287T1 (de) | Neue indol-2-on derivate | |
| JP2005516967A5 (https=) | ||
| PL402388A1 (pl) | Pochodna pirymidyny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca | |
| UA79470C2 (en) | Indole, azaindole and related heterocyclic 4-alkenylpiperidine amides | |
| EA011164B1 (ru) | Производные пиримидина для профилактики вич-инфекции | |
| CY1109490T1 (el) | Τρικυκλικοι τροποποιητες πυρηνικων υποδοχεων στεροειδων ορμονων | |
| HUP0301272A2 (hu) | 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására | |
| JP2020506878A5 (https=) | ||
| CN102971307A (zh) | 作为kv7钾通道开放剂的哌啶基嘧啶酰胺 | |
| SK557685A3 (en) | Alpha-aryl-4-/4,5-dihydro-3,5-dioxo-1,2,4-triazine- -2(3h)yl/benzeneacetonitriles and manufacturing process thereof | |
| PT1335906E (pt) | Derivados de pirimidina e a sua utilização como ligantes de receptores do neuropéptido y | |
| JP2004525183A5 (https=) | ||
| TW200902019A (en) | Dicyclic heterocyclic compound | |
| ATE538784T1 (de) | Verfahren zur behandlung von substanzbedingten erkrankungen | |
| WO2025153625A1 (en) | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |